Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13879MR)

This product GTTS-WQ13879MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13879MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2981MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ2008MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ5806MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ10605MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ11320MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ13308MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ2167MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.